Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the discovery of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Daegu-Gyeongbuk Medical Innovation Foundation and Provibio Co. Ltd. have identified new compounds described as potentially useful for the treatment of cancer and autoimmune diseases.
Cincinnati Children’s Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have jointly patented interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Researchers from Washington University School of Medicine performed studies to assess the role of ZBTB46, a repressive transcription factor and a marker for classical dendritic cells (DCs), in tumor angiogenesis.
Growth differentiation factor 15 (GDF15) is a stress response cytokine overexpressed in several types of cancer that induces weight loss and anorexia and is associated with poor survival. Researchers from Kyinno Biotechnology (Beijing) Ltd. have reported on the preclinical characterization of KY-NAb-GDF15, an anti-GDF15 antibody in models of cancer cachexia.
TYK Medicines Inc. made a strong debut on the main board of the Hong Kong Stock Exchange (HKSE), raising HK$579 million (US$74.32 million) to commercialize its lead compound, EGFR inhibitor TY-9591, now in pivotal trials in patients with EGFR mutation-positive lung cancer.
Adcendo ApS has inked a deal with Multitude Therapeutics Inc. and is licensing Multitude’s phase I-ready antibody-drug conjugate (ADC), ADCE-T02, which targets tissue factor. Under the deal, Copenhagen, Denmark-based Adcendo gains exclusive development and commercialization rights for the ADC globally, excluding greater China (mainland China, Hong Kong, Macao and Taiwan) where Multitude retains all rights.
Copper complexes acting angiogenesis inhibitors have been disclosed in a patent from Istinye Universitesi and Karadeniz Teknik Universitesi Teknoloji Transferi Uygulama ve Arastirma Merkezi as potentially useful for the treatment of cancer.
Recent Beigene Ltd. patents describe condensed heterocyclic compounds acting as diacylglycerol kinase α (DGK-α) and/or DGK-ζ (DGK-ζ) inhibitors and reported to be useful for the treatment of cancer.
Most patients with gastric cancer are diagnosed in advanced stages of the disease. Target identification and unveiling the molecular mechanisms behind it are crucial for this field.
RSS
